Company news

HBM Holdings Ltd. news in 2025

HBM Holdings Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates

December 28, 2025

Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies

December 16, 2025

Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology

November 23, 2025

Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development

November 7, 2025

Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery

October 28, 2025

Harbour BioMed Announces Positive Phase II Results for HBM4003 and Tislelizumab Combination in MSS mCRC

October 21, 2025

Harbour BioMed Reports 2025 Interim Results

August 27, 2025

Harbour BioMed Appoints Yajie Li as Chief Medical Officer

August 24, 2025

Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025

July 29, 2025

Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results

July 27, 2025

HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma

July 23, 2025

Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers

June 22, 2025

China National Intellectual Property Administration Affirms Validity of Harbour BioMed's Patent; Infringement Lawsuit Moves Forward

June 16, 2025

Harbour BioMed Appoints Youchen Chen as Chief Financial Officer

April 9, 2025

Harbour BioMed Reports Full Year 2024 Financial Results

March 31, 2025

Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies

March 21, 2025

Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies

March 12, 2025

Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer

March 9, 2025

Harbour BioMed Appoints Dr. Ian Y. Liu as Global Head of Legal

March 9, 2025

Harbour BioMed and Insilico Medicine Achieve Strategic Collaboration to Advance AI-Driven Antibody Discovery and Development

February 20, 2025

Decks in 2025